Actively Recruiting
Randomized Trial of Reformulated Levulan Kerastick Plus Photodynamic Therapy for Treating Actinic Keratosis on Upper Arms
Led by Sun Pharmaceutical Industries, Inc. · Updated on 2026-11-04
260
Participants Needed
22
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a new formulation of Levulan Kerastick combined with photodynamic therapy PDT to treat actinic keratosis AK on the upper arms. This Phase 3, randomized, multi-center, and evaluator-blind study compares this treatment to a vehicle control in adults with mild to moderate AK lesions. The goal is to see how well the treatment clears the lesions and to assess its safety. Participants will be randomly assigned to receive either the Levulan Kerastick solution or a vehicle solution applied to the skin, followed by an incubation period under occlusion and exposure to blue light using a specialized device. Up to two PDT sessions may be given depending on how well lesions clear. The study includes multiple time points for assessing lesion clearance, cosmetic outcomes, patient satisfaction, and recurrence rates. Throughout the study, participants will be monitored through visits where the skin lesions are evaluated, safety assessments are made including skin reactions and lab tests, and patient feedback is collected. The primary outcome focuses on the complete clearance rate of AK lesions at Week 12. Secondary outcomes involve lesion clearance at various weeks up to 24, cosmetic responses, and recurrence. The total study duration includes treatment and follow-up assessments extending to Week 24.
CONDITIONS
Brief Title
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Research Team
H
Head, Regulatory Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here